Business Model Breakdown
How Puma Biotechnology Inc Makes Money
PBYI
Market Cap
$382M
Annual Revenue
$238M
Profit Margin
13.6%
Employees
172
The Short Version
Puma Biotechnology Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. Its primary source of revenue comes from the sales of its flagship product, NERLYNX (neratinib), an oral medication used for certain types of HER2-positive breast cancer. The company generates revenue by selling this drug to healthcare providers who prescribe it to eligible patients, managing distribution, and supporting its clinical use.
Where the Revenue Comes From
Sales of NERLYNX (neratinib) (~100% of reported revenue)
Who buys: Oncologists, hospitals, and specialty pharmacies treating patients with HER2-positive breast cancer.
Why It Works (Competitive Advantages)
- ✔Approved drug (NERLYNX) with established market presence for specific HER2+ breast cancer indications.
- ✔Intangible assets in the form of intellectual property and regulatory approvals.
Economic Moat: Narrow (Intangible Assets/IP (FDA approval and patent protection for NERLYNX))
What Our Analysis Says
DVR Score as of April 28, 2026
Puma Biotechnology remains a highly speculative investment with limited 10x growth potential within 3-5 years. While the company exhibits a strong balance sheet and explicitly positive TTM free cash flow ($41.73M), which provides financial stability, the core business faces significant headwinds. Previous intelligence indicated declining new prescriptions for NERLYNX and a projected revenue decline and net loss for Q1 2026. No new catalysts, such as the previously anticipated Alisertib data, have emerged to offset this contraction. The proposed extension of the CEO's warrant introduces potential dilution concerns. Despite an extremely low P/S ratio of 1.0x, the very low consensus FY26 EPS ($0.14) suggests ongoing earnings contraction, making the valuation appear cheap but without clear growth drivers. The company lacks a compelling vision for capturing significant market share or a clear competitive advantage that is expanding. **Score Change Explanation:** The score is increased from 17/100 to 20/100. This adjustment is primarily due to the explicit confirmation of positive Trailing Twelve Month (TTM) Free Cash Flow ($41.73M) and Operating Cash Flow ($41.80M), which provides a clearer picture of the company's financial resilience and ability to self-fund operations, reinforcing the previously noted 'strong balance sheet.' Furthermore, the current valuation metrics, specifically a P/S of 1.0x (vs. sector 3.3x) suggest deep undervaluation relative to its current (even if challenged) revenue base. While the core challenges of declining NERLYNX new prescriptions and the lack of a clear 10x growth catalyst (e.g., Alisertib data) persist, and the proposed CEO warrant extension introduces potential dilution concerns, the solid cash generation and extremely low P/S provide a marginally stronger foundation than previously understood, mitigating some downside risk and offering speculative turnaround potential. The previous analysis's projection of Q1 2026 decline and net loss, and declining NERLYNX prescriptions, are assumed to still be relevant as they were not contradicted by the current research.